Did all patients receive LL and an ICI? CytoDyn
Post# of 157355
(Total Views: 1236)
Posted On: 09/26/2025 4:44:51 PM
Did all patients receive LL and an ICI?
CytoDyn (OTCQB: CYDY) will present significant findings on leronlimab's effectiveness in treating metastatic triple-negative breast cancer (mTNBC) at the AACR Special Conference in Montreal. The company's retrospective analysis of 28 patients revealed that leronlimab, when administered at doses >525mg/week, induced PD-L1 expression in 88% of patients.
Key clinical findings showed that 5 out of 5 patients who received both leronlimab and immune checkpoint inhibitors (ICIs) remain alive after approximately 60 months of treatment. The study demonstrated that 18% of heavily pretreated mTNBC patient survived after a median of ~60 months when treated with CCR5 inhibition combined with ICI therapy.
The research suggests leronlimab could potentially enhance the effectiveness of checkpoint inhibitors in treating solid tumors, particularly in cases previously resistant to such treatments.
CytoDyn (OTCQB: CYDY) will present significant findings on leronlimab's effectiveness in treating metastatic triple-negative breast cancer (mTNBC) at the AACR Special Conference in Montreal. The company's retrospective analysis of 28 patients revealed that leronlimab, when administered at doses >525mg/week, induced PD-L1 expression in 88% of patients.
Key clinical findings showed that 5 out of 5 patients who received both leronlimab and immune checkpoint inhibitors (ICIs) remain alive after approximately 60 months of treatment. The study demonstrated that 18% of heavily pretreated mTNBC patient survived after a median of ~60 months when treated with CCR5 inhibition combined with ICI therapy.
The research suggests leronlimab could potentially enhance the effectiveness of checkpoint inhibitors in treating solid tumors, particularly in cases previously resistant to such treatments.
(3)
(0)